News
Flu vaccination linked to a 40 per cent reduction in risk of Alzheimer
A new research led by the University of Texas Health Science Center at Houston has found a connection between flu vaccination and a 40 per cent reduced risk of Alzheimer.

Researchers have found a close link between the flu vaccination and a 40 per cent reduced risk of Alzheimer.
Focusing on Americans aged 65 and older, the study compared the risk of Alzheimer’s disease between patients with and without prior flu vaccination.
The research, conducted by The University of Texas at Austin , follows previous research from the university, that already found a possible link between the flu vaccine and a reduced risk of Alzheimer disease two years ago.
To collect the data needed, the researchers analysed the numbers of 935,887 flu-vaccinated patients and 935,887 non-vaccinated patients over the course of four years. During the appointments with the patients, 8.5 per cent of non-vaccinated patients developed Alzheimer’s disease against a 5.1 per cent of flu-vaccinated patients.
The results of the research paper only covered a small part of the underlying mechanisms of Alzheimer’s disease and its connection with the flu vaccine, which leaves space for further research.
One of the researchers, Dr Shoulz, stated that the reduction of the risk of Alzheimer’s disease is not a specific effect of the flu vaccine.
He added “Instead, we believe that the immune system is complex, and some alterations, such as pneumonia, may activate it in a way that makes Alzheimer’s disease worse. But other things that activate the immune system may do so in a different way – one that protects from Alzheimer’s disease.
“Clearly, we have more to learn about how the immune system worsens or improves outcomes in this disease.”
“We found that the flu vaccination in older adults reduces the risk of developing Alzheimer’s disease for several years. The strength of this protective effect increased with the number of years that a person received an annual flu vaccine,” said Bukhbinder, the first author of the research.
“Future research should assess whether flu vaccination is also associated with the rate of symptom progression in patients who already have Alzheimer’s dementia,” he added.

Following this finding that connect the flu vaccine to a reduced risk of Alzheimer’s disease, Dr Bukhbinder shared his interest in undertaking further research to understand whether a similar association exists between COVID-19 vaccination and Alzheimer.
Past studies have already showed a decreased risk of dementia associated with exposure to various vaccinations, such as polio, herpes and tetanus.
Although this new case study used a large sample, studies with longer follow-up periods are desirable as the symptoms of Alzheimer only appear decades after the pathology begins.
Alzheimer affects six million people in the US and over 850,000 people in the UK, according to a 2019 study.
This means that one in every 14 people of the population aged 65 years and over are affected by the Alzheimer’s disease. According to the Alzheimer’s Society, people with Dementia will increase to 1.5 million people by 2040 in the UK alone. This growth in elderly people affected by Alzheimer is expected to be steady if no action is taken.
Worldwide, numbers of people living with dementia are expected to double every 20 years. By 2050 the people with dementia will be 115 million against 36 million nowadays. The current estimated cost of dementia worldwide is £380 bn (US$604 billion).
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.








